The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

OBJECTIVES: HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy‐experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long‐term adverse events (AEs). This open‐label, multicentre, noninferiority...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:HIV Med
Autori principali: Wohl, DA, Bhatti, L, Small, CB, Edelstein, H, Zhao, HH, Margolis, DA, DeJesus, E, Weinberg, WG, Ross, LL, Shaefer, MS
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2015
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034844/
https://ncbi.nlm.nih.gov/pubmed/26176344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hiv.12281
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi